A Phase 3 Randomized Double-blind Study of Adjuvant Pembrolizumab With or Without V940 in Participants With Resectable Stage II to IIIB (N2) NSCLC Not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy (INTerpath-009)
Latest Information Update: 04 Nov 2024
At a glance
- Drugs MRNA 4157 (Primary) ; Pembrolizumab (Primary) ; Carboplatin; Cisplatin; Gemcitabine; Paclitaxel; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms INTerpath-009
- Sponsors Merck Sharp & Dohme
- 28 Oct 2024 According to a Merck & Co media release, company announced initiation of INTerpath-009 trial and global recruitment in INTerpath-009 has begun, and the first patients have now started enrolling in Canada.
- 28 Oct 2024 Status changed from not yet recruiting to recruiting.
- 08 Oct 2024 New trial record